Ratings Pharming Group N.V. Nasdaq

Equities

PHAR

US71716E1055

Market Closed - Nasdaq Other stock markets 21:30:00 14/06/2024 BST			5-day change	1st Jan Change
8.6 ^USD	+0.04%		+1.90%	-24.76%

05-31	Pharming Group Flags Delay in EU Review of Rare Immunodeficiency Drug	MT
05-30	Pharming Group N.V. Provides Update on Ongoing Regulatory Review of Leniolisib for the Treatment of Apds in the European Union	CI

Summary

From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 55% by 2026.
The company is in a robust financial situation considering its net cash and margin position.
Over the last twelve months, the sales forecast has been frequently revised upwards.
Analysts covering this company mostly recommend stock overweighting or purchase.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Analyst opinion has improved significantly over the past four months.

Weaknesses

As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
The company does not generate enough profits, which is an alarming weak point.
The valuation of the company is particularly high given the cash flows generated by its activity.
For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.

Ratings chart - Surperformance

Sector: Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
PHARMING GROUP N.V.	-24.76%	535M	-
NOVO NORDISK A/S	+42.19%	630B	B
JOHNSON & JOHNSON	-7.15%	350B	C+
MERCK & CO., INC.	+18.77%	328B	B-
ABBVIE INC.	+8.79%	298B	C+
ASTRAZENECA PLC	+17.98%	246B	B+
ROCHE HOLDING AG	+0.61%	225B	A+
NOVARTIS AG	+10.76%	218B	B-
AMGEN INC.	+3.68%	160B	C+
PFIZER, INC.	-4.38%	156B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes